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ABSTRACT
INTRODUCTION: Acute phase response represents an increase in hepatic production of the so-called 
acute phase proteins (APP). Until now, C-reactive protein (CRP) has routinely been measured as an indica-
tion of bacterial infections. Serum amyloid A (SAA) is a novel marker. It is a more conservative protein for 
viral etiology of the disease. We analyzed the dynamic changes of SAA and CRP during influenza infection 
and evaluated the role of SAA as a significant marker for viral infections. 
MATERIALS AND METHODS: We studied 31 patients with clinically suspected and serologically proved 
influenza, hospitalized in the Department of Infectious Diseases at St. Marina University Hospital, Varna. 
Serum levels of SAA and CRP were measured on admission and 4.23±1.03 days later by immunoturbidimet-
ric assays, adapted on Olympus AU 400. 
RESULTS: The mean serum concentrations of SAA during the acute stage were 168.92 mg/L and those of 
CRP were 48.08 mg/L. In the group of bacterial complications, such as bronchitis, sinusitis and otitis media, 
the SAA levels were 5- to 9-fold greater than CRP. Analyses of the second measurement showed a tendency 
of serum SAA to disappear more quickly than CRP - 52.11 mg/L vs. 16.71 mg/L.
CONCLUSION: SAA is more sensitive APP than CRP in viral infection settings. In cases of bacterial su-
perinfections, serum SAA is more predominant than CRP, indicating the necessity of an antibiotic therapy. 
Prompt downgrading of SAA in sera correlates with auspicious prognosis could be used as an effective treat-
ment monitoring. Scr Sci Med. 2017;50(1):15-19
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INTRODUCTION 
Infectious diseases run their clinical course as 
result of inflammation caused by viral or bacteri-
al infection. It leads to acute phase response (APR) 
from the immune system, mediated by hepatic pro-
duction of more than 200 acute phase proteins (APP) 
(1). Measurement of some of them in the patient’s 
sera is helpful to early diagnosis, differential diagno-
sis and evaluation of the effect of the initiated treat-
ment (2,3). The first described APP is C-reactive pro-
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tein (CRP) and it is routinely measured today as an 
indicative marker for acute bacterial infections when 
its serum concentrations are high (4). Novel investi-
gations are focused on another APP named serum 
amyloid A protein (SAA) (4,5). First, its function was 
not exactly clear and it was described in the literature 
as a protein without function (6). Years later it was 
found that it acts as an apolipoprotein of high-den-
sity lipoproteins (HDL), increasing in the serum up 
to 1000-fold in response to inflammation. Various 
international studies show that SAA may be a more 
sensitive inflammatory marker than CRP, especially 
during viral infections, where CRP changes are in a 
narrower range (7,8,9).
AIM
The aim of the study is to investigate the cor-
relation between SAA and CRP in influenza and to 
assess the role of SAA as a significant marker for in-
flammation with viral causes. To achieve it, we evalu-
ated SAA/CRP kinetics in non-complicated influen-
za cases; SAA/CRP kinetics in complicated influen-
za cases; correlation between SAA and CRP changes; 
and the possibility for SAA to be used as a marker for 
early effective treatment response.
Material and Methods: The prospectively 
studied group consisted of 31 patients with influen-
za, hospitalized in the Department of Infectious Dis-
eases at the St. Marina University Hospital, Varna, 
Bulgaria in the period December 2014 – February 
2016. The patients were between 1 and 60 years old 
and did not suffer from any chronic diseases. They 
were divided into 2 subgroups: non-complicated in-
fluenza – 21 patients and complicated influenza – 10 
patients. The diagnosis was proven by clinical/epide-
miological observations and serological analysis for 
anti-influenza IgM/IgG in the serum sample on the 
day of admission. For measuring the serum levels of 
SAA and CRP immunoturbidimetric assays, adapted 
on Olympus AU 400 were used. Reference ranges for 
SAA were up to 10 mg/L and for CRP – up to 5 mg/L 
based on the aforementioned techniques. 
RESULTS
Our study included 31 patients with influenza. 
The sex and age distribution are shown on Fig. 1 and 
Fig. 2, respectively. 
Twenty-one of them became acutely ill 1 day be-
fore hospitalization, 7 – 2 days before hospitalization 
and in just 3 patients the diagnosis was suspected 3 
days prior to hospitalization. All patients had clinical 
signs and symptoms highly suspicious of seasonal in-
fluenza: acute onset of fever more than 38.6ºC, severe 
myalgias, fatigue and weakness, frontal and retro-or-
bital headache, dry cough. 
During the period of hospitalization, 7 patients 
had complications of acute bronchitis, 1 - pneumo-
nia, 1 – sinusitis, and 1 - otitis media (Tab. 1). 
All 31 patients were analyzed twice for SAA 
and CRP – first on the day of admission and second 
4.23±1.03 days later. 
On the day of admission higher than normal 
SAA was detected in 28 patients (90.32%) while in 3 
(9.68%) of them it was within the reference range. In 
regard to CRP – it was increased in 24 cases (77.42%) 
and normal in 7 (22.58%). The mean SAA concentra-
Fig. 1. Sex distribution of the patients – 17 (54.84%) men 
and 14 (45.16%) women
Fig. 2. Age distribution of the patients
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tion was significantly higher than CRP: 168.92 mg/L 
versus 48.08 mg/L.
In the subgroup of non-complicated influenza, 
the mean value of SAA was 157.55 mg/L, with the 
highest concentration of 655.9 mg/L measured in one 
46-year-old male patient. As it was mentioned above 
11 patients became ill just 1 day before hospitaliza-
tion. Their mean level of SAA was 55.4 mg/L. 
The serum levels of CRP in the same subgroup 
showed a mean value of 53.16 mg/L, which was 8.56 
mg/L for those who became ill 1 day prior to hospi-
talization (Fig. 3).
The SAA/CRP mean ranges in the complicat-
ed cases of influenza were 202.0 mg/L versus 37.30 
mg/L. Extremely high SAA was observed in the pa-
tients with acute bronchitis (1041.0 mg/L), acute si-
nusitis (390.4 mg/L), and acute otitis media (281.3 
mg/L). In these cases, the serum levels of CRP were 
166.98, 72.51, and 8.22 mg/L, respectively.
The mean value of SAA for all 31 patients from 
the second sample was 52.11 mg/L versus 16.71 mg/L 
for CRP. SAA was normal in 22 patients (70.97%) 
while 9 (29.03%) sera probes reacted with increased 
SAA up to 982.7 mg/L. CRP was normal in 21 
(67.74%) and abnormal in 10 (32.26%) patients. 
Illness characteristic 1-3 years 4-7 years 8-14 years 15-45 years 46-60 years
Disease onset:
 1 day before admission / 
11-35.48% of the patients/
 2 days before admission  
/7-22.58% of the patients/
 3 day before admission  




























Mean temperature on admission, ºC 39.1±1.0 38.9±1.1 38.7±0.9 38.7±1.0 39.2±0.9
Disease duration in days 4.66±1.0 4.5±0.95 4.5±0.96 3.92±1.01 3.5±0.1
Complications:
 Acute bronchitis 
 Acute pneumonia 
 Acute otitis media 



















Table 1. Patients and illness characteristics
Fig. 3. Mean SAA/CRP value from the first serum sample 
in the group of non-complicated cases
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In the subgroup of non-complicated cases mean 
SAA/CRP levels from the second serum sample were 
27.96/15.02 mg/L. Normal value of SAA was regis-
tered in all of the patients with a 3-day history of ill-
ness while CRP was normal just in 5 of them (Fig. 4). 
In the complicated influenza subgroup, the sec-
ond sample showed mean SAA value of 102.0 mg/L 
and mean CRP value of 100.16 mg/L. 
DISCUSSION
Human acute phase SAA is α-globulin, which 
belongs to the apolipoprotein family (10). Its func-
tions are still not fully understood (11). Some of the 
most important ones are inhibition of antibody pro-
duction, mediation of fever and platelet aggregation, 
together with induction of chemotaxis and some 
proteases (12,13,14,15). 
Increased serum SAA concentrations have been 
reported in various viral infections, such as influen-
za, rhinovirus, measles, chickenpox, hand-foot-and-
mouth disease, etc. (16,17). Such propositions corre-
late with the results of our study, where 90.32% of the 
patients with influenza showed significant increase 
of SAA concentration in the acute phase of the dis-
ease with a mean 16-fold increase over the refer-
ence range. Different studies introduce data about 
more conservative changes in CRP concentrations 
in the course of viral infections and it is common-
ly increased in bacterial cases (1,4,18). In our patients 
the mean CRP value from the first serum samples 
is 48.08 mg/L in contrast to the mean value of SAA 
– 168.92 mg/L. This statement confirms important 
current data about measuring SAA as a sensitive 
marker for inflammation with viral causes in situa-
tions when CRP is also reactive (2). 
Serum amyloid A is the earliest APP which ap-
pears in the serum 3-6 hours after acute inflamma-
tions. C-reactive protein kinetics parallel that but is 
less pronounced (4,18). The same changes are ob-
served in our study – mean value of SAA in the pa-
tients with a 1-day illness history is 55.4 mg/L for 
SAA versus 8.56 mg/L for CRP. 
According to Nakayama et al., the maximum 
value of SAA is observed 48 hours after the onset of 
the inflammation, returning to baseline 4-5 days lat-
er (19). CRP changes are the same but more conserva-
tive. Our results confirm these data – the mean value 
of SAA is 3 times below the initial (52.11 mg/L) while 
CRP is decreased to a lesser extent (16.71 mg/L). So, 
SAA is a significant marker for early clinical im-
provement. Patients whose inflammatory markers 
are still abnormal and have not had full recovery re-
quire high medical attention and therapy revision.
Significant difference is observed in the initial 
range of SAA/CRP in non-complicated and compli-
cated subgroups. In the first subgroup mean SAA is 
157.55 mg/L, and in the second – 202.0 mg/L, while 
CRP changes are roughly similar (53.16/37.30 mg/L). 
It means that extremely high SAA (>200 mg/L) in-
dicates possible bacterial complication and calls for 
empiric antibiotic treatment. The same results may 
be seen in the study of Chambers et al., who suggest 
that SAA is of value in monitoring the severity of the 
inflammation and the recovery process in viral in-
fections (20). The second samples in both subgroups 
show a significant decrease in the evaluated markers, 
but in the group of complicated forms, the results are 
the opposite – decrease of SAA and increase of CRP. 
In this context, SAA may be an early marker for ef-
fective treatment monitoring.    
CONCLUSION 
In viral infections SAA is a more sensitive APP 
than CRP. In the cases of bacterial superinfections, 
serum SAA is higher than CRP, indicating a neces-
sity of antibiotic therapy. Prompt downgrading of 
SAA in sera correlates with auspicious prognosis and 
could be used as an effective treatment monitoring.
Fig. 4. Mean SAA/CRP value from the second serum sam-
ple in the group of non-complicated cases
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